Pz Wind Down, Inc., formerly, PhaseRx, Inc. is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company's initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body's inability to remove ammonia from the blood. The Company's i-ERT approach is enabled by its Hybrid mRNA Technology platform and is applicable to a number of inherited liver diseases. The Company is headquartered in Seattle.
Metrics to compare | PZRXQ | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPZRXQPeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | −3.8x | −0.6x | |
PEG Ratio | 0.00 | 0.18 | 0.00 | |
Price/Book | 0.0x | 2.0x | 2.6x | |
Price / LTM Sales | 0.0x | 20.4x | 3.1x | |
Upside (Analyst Target) | 0.0% | 122.9% | 56.7% | |
Fair Value Upside | Unlock | 10.1% | 7.8% | Unlock |